Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.

from Latest articles from Cancer Therapy Advisor Male Reproductive Cancers http://bit.ly/2TLu3wc